Virtual Panel Discussion - Present and Future of Human Metabolomics (for Research Use Only)
Human metabolomics has seen a rapid rise in the world of Omics and is currently a major source of funding in many countries globally. Today, a lot of emphasis is also put on COVID 19 Research, and Metabolomics will play a substantial role in this as well. One of the main technologies applicable in Human Metabolomics, NMR is based on a standardized approach to the generation of high-quality spectra of human body fluids covering plasma, urine, CSF, serum, and methanol extracts from body fluids, cells, and tissues.
Bruker hosted a live Virtual Discussion, in which panelists shared experiences and different perspectives on NMR-based human metabolomics in the diverse application research areas.
The group leader of the Precision Medicine and Metabolism group of the CIC bioGUNE, Dr. Oscar Millet’s research is concentrated on the use of nuclear magnetic resonance (NMR) in the study of biologically relevant enzymes and proteins, paying special attention to the extraction of metabolic information from biological samples like urine and serum. Dr. Millet has been the recipient of the Real Sociedad Española de Química prize (2004), the Innovation Award of the Basque Government (2018) and the Spanish NMR group prize (2005). He is the scientific founder of the spin-off Atlas Molecular Pharma and is the president of the Spanish Chemical Biology Group.
Professor Gary Frost is currently the head of the Section for Nutrition Research and the lead of the Imperial Nutrition and Food Network. Having qualified as a dietitian in 1982, Prof. Frost has always maintained a clinical input throughout his career. Before being appointed Professor of Nutrition and Dietetics at Imperial College Jan 2008, Gary worked for 18 years at Hammersmith Hospital. During his time at Hammersmith, Professor Frost gained his Ph.D. in Nutrition and was appointed Honorary Reader in Nutrition at Imperial College, before joining the University of Surrey as a Professor of Nutrition and Dietetics in 2005.
Dr. Tone Frost Bathen is head of the MR Cancer Group. Dr. Bathen’s main research interests are in studies of functional and metabolic properties of cancer and personalized medicine as well as using magnetic resonance imaging (MRI) and spectroscopy (MRS).
The group’s goal is to establish better diagnostic tools for the stratification of patients to treatment and treatment monitoring by developing, optimizing, and applying advanced MR (in combination with other molecular methods) to characterize cancer. Current research activities, enabled by close collaboration with St. Olav’s University Hospital in Trondheim, mainly focus on breast and prostate cancer. Even though clinical research has high priority, the broad spectrum of systems for cancer studies offers translational research, covering both ex vivo and in vivo MRI and MRS of cancer cells and laboratory animals. Bathen’s group also has a number of large biobanks of biofluid samples and human tissue.